Medifast Announces Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Medifast (MED) PT Lowered to $16.50 at DA Davidson
August 6, 2024 5:05 AM EDTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $16.50 (from $17.50) while maintaining a Underperform rating.
The analyst comments "UNDERPERFORM-rated MED reported a 2Q24 sales miss but profit beat. MED guided 3Q sales below the Street; the EPS... More
